388 related articles for article (PubMed ID: 33434950)
1. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
Cavalcante RS; Ishikawa U; Silva ES; Silva-Júnior AA; Araújo AA; Cruz LJ; Chan AB; de Araújo Júnior RF
Br J Pharmacol; 2021 Jun; 178(11):2284-2304. PubMed ID: 33434950
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of murine colorectal cancer metastasis by targeting M2-TAM through STAT3/NF-kB/AKT signaling using macrophage 1-derived extracellular vesicles loaded with oxaliplatin, retinoic acid, and Libidibia ferrea.
de Carvalho TG; Lara P; Jorquera-Cordero C; Aragão CFS; de Santana Oliveira A; Garcia VB; de Paiva Souza SV; Schomann T; Soares LAL; da Matta Guedes PM; de Araújo Júnior RF
Biomed Pharmacother; 2023 Dec; 168():115663. PubMed ID: 37832408
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid-loaded PLGA nanocarriers targeting cell cholesterol potentialize the antitumour effect of PD-L1 antibody by preventing epithelial-mesenchymal transition mediated by M2-TAM in colorectal cancer.
Júnior RFA; Lira GA; Schomann T; Cavalcante RS; Vilar NF; de Paula RCM; Gomes RF; Chung CK; Jorquera-Cordero C; Vepris O; Chan AB; Cruz LJ
Transl Oncol; 2023 May; 31():101647. PubMed ID: 36857852
[TBL] [Abstract][Full Text] [Related]
4. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
6. CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3.
Zhao C; Zeng N; Zhou X; Tan Y; Wang Y; Zhang J; Wu Y; Zhang Q
BMC Cancer; 2023 May; 23(1):392. PubMed ID: 37127625
[TBL] [Abstract][Full Text] [Related]
7. YAP/STAT3 inhibited CD8
Wang C; Shen N; Guo Q; Tan X; He S
Cancer Med; 2023 Aug; 12(15):16295-16309. PubMed ID: 37329188
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
[TBL] [Abstract][Full Text] [Related]
9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
10. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
11. Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes.
Bi S; Huang W; Chen S; Huang C; Li C; Guo Z; Yang J; Zhu J; Song L; Yu R
Int J Biol Macromol; 2020 May; 150():261-280. PubMed ID: 32044366
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicles from M1-Polarized Macrophages Combined with Hyaluronic Acid and a β-Blocker Potentiate Doxorubicin's Antitumor Activity by Downregulating Tumor-Associated Macrophages in Breast Cancer.
Jorquera-Cordero C; Lara P; Cruz LJ; Schomann T; van Hofslot A; de Carvalho TG; Guedes PMDM; Creemers L; Koning RI; Chan AB; de Araujo Junior RF
Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631654
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
Jang YS; Kim TW; Ryu JS; Kong HJ; Jang SH; Nam GH; Kim JH; Jeon S
PLoS One; 2023; 18(2):e0277285. PubMed ID: 36757936
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer cells promote CD169
Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
16. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis.
Pradhan R; Paul S; Acharya SS; Sinha S; Dash SR; Kundu CN
J Nutr Biochem; 2024 Mar; 125():109568. PubMed ID: 38185347
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
Ju X; Zhang H; Zhou Z; Chen M; Wang Q
Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
[TBL] [Abstract][Full Text] [Related]
18. YAP/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-TGFβ signaling to facilitate PD-L1 expression in M2-like TAMs.
Du XX; He C; Lu X; Guo YL; Chen ZH; Cai LJ
Exp Cell Res; 2021 Aug; 405(2):112655. PubMed ID: 34044017
[TBL] [Abstract][Full Text] [Related]
19. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
20. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
